Becton, Dickinson and Company (NYSE:BDX) Shares Sold by Vinva Investment Management Ltd

Vinva Investment Management Ltd cut its stake in Becton, Dickinson and Company (NYSE:BDX) by 19.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 16,304 shares of the medical instruments supplier’s stock after selling 3,939 shares during the quarter. Vinva Investment Management Ltd’s holdings in Becton, Dickinson and Company were worth $3,938,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of BDX. Public Sector Pension Investment Board increased its position in shares of Becton, Dickinson and Company by 12.5% in the third quarter. Public Sector Pension Investment Board now owns 12,566 shares of the medical instruments supplier’s stock valued at $3,030,000 after buying an additional 1,400 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Becton, Dickinson and Company by 6.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 70,906 shares of the medical instruments supplier’s stock worth $17,095,000 after purchasing an additional 4,114 shares in the last quarter. Providence Capital Advisors LLC grew its holdings in Becton, Dickinson and Company by 1.2% in the 3rd quarter. Providence Capital Advisors LLC now owns 18,740 shares of the medical instruments supplier’s stock valued at $4,518,000 after buying an additional 216 shares in the last quarter. CreativeOne Wealth LLC grew its holdings in Becton, Dickinson and Company by 147.5% in the 3rd quarter. CreativeOne Wealth LLC now owns 2,185 shares of the medical instruments supplier’s stock valued at $527,000 after buying an additional 1,302 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund grew its holdings in Becton, Dickinson and Company by 2.0% in the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 157,038 shares of the medical instruments supplier’s stock valued at $37,862,000 after buying an additional 3,035 shares in the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Trading Down 1.0 %

NYSE:BDX opened at $221.98 on Friday. The stock’s 50 day moving average price is $234.39 and its 200 day moving average price is $234.23. The company has a market capitalization of $64.16 billion, a PE ratio of 37.37, a P/E/G ratio of 1.68 and a beta of 0.43. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $249.89.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, topping analysts’ consensus estimates of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The company had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same period last year, the firm earned $3.42 EPS. The firm’s revenue for the quarter was up 6.9% on a year-over-year basis. On average, research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th will be given a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 1.87%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. The ex-dividend date of this dividend is Monday, December 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 63.97%.

Wall Street Analysts Forecast Growth

BDX has been the topic of several recent analyst reports. Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their price target for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. Evercore ISI increased their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Raymond James cut their price target on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. Finally, StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average price target of $283.00.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.